歌禮製藥(01672.HK)ASC30美國IIa期研究已完成入組
歌禮製藥-B(01672.HK)公布,評估小分子口服GLP-1受體(GLP-1R)激動劑ASC30治療肥胖症的美國13周IIa期研究已完成入組。125例受試者均為肥胖人群或伴有至少一種體重相關合併症的超重人群。
歌禮創始人、董事會主席兼首席執行官吳勁梓博士表示,熱切期待在2025年第四季度獲得這項IIa期研究的頂線數據。作為一種小分子藥物,如獲批,ASC30有望提供每日一次口服和每月一次皮下注射兩種給藥選擇治療肥胖症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.